SEC Form 4 · accession 0001209191-16-126260

Clearside Biomedical, Inc. · CLSD

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Clay Thorp

Director · 10% Owner

Period of report

Jun 7, 2016

Accepted (ET)

Jun 7, 2016 · 4:31 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001539029

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3,F4	Jun 7, 2016	C	3,321,785	—	A	3,433,833	I	See Footnotes
Common Stock^F3,F4	Jun 7, 2016	X	43,410	$0.022	A	3,477,243	I	See Footnotes
Common Stock^F3,F4	Jun 7, 2016	S	138	$7.00	D	3,477,105	I	See Footnotes
Common Stock^F3,F4	Jun 7, 2016	P	785,714	$7.00	A	4,262,819	I	See Footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A Preferred Stock^F3,F4,F2	—	Jun 7, 2016	C	4,071,815	D	—	—	Common Stock	1,850,823	I
Series A-1 Preferred Stock^F3,F4,F2	—	Jun 7, 2016	C	1,654,531	D	—	—	Common Stock	752,058	I
Series B Preferred Stock^F3,F4,F2	—	Jun 7, 2016	C	865,881	D	—	—	Common Stock	393,581	I
Series C Preferred Stock^F3,F4,F2	—	Jun 7, 2016	C	675,795	D	—	—	Common Stock	325,323	I
Warrant to Purchase Common Stock (right to buy)^F3,F4,F7,F6	$0.022	Jun 7, 2016	X	19,900	D	Apr 28, 2014	—	Common Stock	19,900	I
Warrant to Purchase Common Stock (right to buy)^F3,F4,F8,F6	$0.022	Jun 7, 2016	X	1,805	D	Apr 28, 2014	—	Common Stock	1,805	I
Warrant to Purchase Common Stock (right to buy)^F3,F4,F9,F6	$0.022	Jun 7, 2016	X	21,705	D	Apr 28, 2014	—	Common Stock	21,705	I

Explanation of responses

F1The total represents shares received upon conversion of shares of Series A Preferred Stock, Series A-1 Preferred Stock, Series B Preferred Stock and Series C Preferred Stock.
F2Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock, Series A-1 Preferred Stock and Series B Preferred Stock automatically converted into 0.454545 shares of the Issuer's common stock, and each share of Series C Preferred Stock automatically converted into 0.4814 shares of the Issuer's common stock. The Preferred Stock had no expiration date.
F3The reporting person is one of the general partners of: (i) Hatteras Venture Advisors III, LLC, the general partner of Hatteras Venture Partners III, LP ("HVP III") and Hatteras Venture Affiliates III, LP ("HVA III"); (ii) Hatteras Venture Advisors IV SBIC, LLC, the general partner of Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC"); and (iii) Hatteras Venture Advisors IV, LLC, the general partner of Hatteras Venture Partners IV, LP ("HVP IV") and Hatteras NC Fund, LP ("Hatteras NC"). HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC are the record holders of the securities, and the reporting person may be deemed to share voting and dispositive power over the securities held by HVP III, HVA III, HVP IV SBIC, HVP IV and Hatteras NC.
F4The reporting person disclaims beneficial ownership of these securities and this report is not an admission that the reporting person is a beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.
F5On June 7, 2016, HVP III, HVA III and HVP IV SBIC exercised warrants to purchase an aggregate of 43,410 shares of Issuer's common stock for $0.022 per share. HVP III, HVA III and HVP IV SBIC paid the exercise price on a cashless basis, resulting in the Issuer's withholding of an aggregate of 138 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 43,272 shares.
F6This warrant would have expired upon the closing of the Issuer's initial public offering.
F7This warrant was held directly by HVP III.
F8This warrant was held directly by HVA III.
F9This warrant was held directly by HVP IV SBIC.